<DOC>
	<DOCNO>NCT02883374</DOCNO>
	<brief_summary>The purpose trial evaluate efficiency safety Chidamide advance cephalic cervical adenoid cystic carcinoma . Chidamide give patient advance cephalic cervical adenoid cystic carcinoma dosage 30mg , twice week , overall survival , event-free survival access efficiency , laboratory test function vital organ access safety .</brief_summary>
	<brief_title>Chidamide Advanced Cephalic Cervical Adenocystic Carcinoma : Evaluation Efficiency Safety</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<criteria>1 . Patients advance cephalic cervical adenocystic carcinoma pathological imaging evidence , local relapse metastasis refractory towards treatment . 2 . Age 1875 , male female , expect survival≥ 3 month . 3 . ECOG 02 . 4 . With least one evaluable disease focus . 5 . Organ function fit follow : Liver : Total bilirubin ≤ 1.5 time normal maximum , ALT AST≤ 2.5 time normal maximum . ( ALT/AST≤ 5 time normal maximum patient infiltrative liver disease ) Kidney : Serum creatinine ˂ 1.5 fold normal maximum ; creatinine clearance rate ≥50ml/min ( calculate CockroftGault10 formula ) 1 . History HDACI treatment . 2 . Women pregnancy lactation . 3 . Patients second primary tumor ( include nonmelanoma skin cancer receive systemic treatment , cure cervical carcinoma situ uterus , tumor cure disease free survival˃ 5 year ) 4 . Patients central nervous system defect mental disorder . 5 . Other disease contraindication : History heart disease within 6 month prior inclusion , include NYHA III—IV heart failure treatment , coronary heart disease , angina pectoris , myocardial infarction , degree II III atrioventricular block , severe arrhythmia need medical treatment , uncontrolled hypertension ; liver cirrhosis ( ChildPugh B C ) ; active infection control , condition may make patient unable complete trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cephalic cervical adenocystic Carcinoma</keyword>
	<keyword>Chidamide</keyword>
</DOC>